Study of Ataluren (PTC124) in Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title:

An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02107859
• Other study ID #: PTC124-GD-023-CF
• Secondary ID: 2013-005449-35
• Status: Terminated
• Phase: Phase 3
• Start date: May 23, 2014
• Est. completion date: June 5, 2017

Study information

• Verified date: March 2020
• Source: PTC Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the long-term safety and tolerability of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) who completed participation in the double-blind study PTC124-GD-009-CF (NCT00803205), as assessed by adverse events and laboratory abnormalities. The secondary objective of this study includes the assessment of the efficacy of ataluren, as measured by forced expiratory volume in 1 second (FEV1) and pulmonary exacerbation rate, and other safety parameters (for example, 12-lead electrocardiogram [ECG] measurements, vital signs).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 61
• Est. completion date: June 5, 2017
• Est. primary completion date: June 5, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Key Inclusion Criteria:

• Ability to provide written informed consent (parental/guardian consent and participant assent if less than [<] 18 years of age).

• Evidence of completed participation in the double-blind study, PTC124-GD-009-CF (Study 009).

• Body weight greater than or equal to (=) 16 kilograms (kg).

• Performance of a valid, reproducible spirometry test using the study-specific spirometer during the screening period.

• Confirmed laboratory values within the central laboratory ranges at screening.

• In male and female participants who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 60-day follow-up period.

• Willingness and ability to comply with all study procedures and assessments, including scheduled visits, drug administration plan, laboratory tests, and study restrictions.

Key Exclusion Criteria:

• Chronic use of systemic tobramycin within 4 weeks prior to screening.

• Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to screening or between screening and randomization.

• Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to screening and randomization.

• Known hypersensitivity to any of the ingredients or excipients of the study drug.

• Exposure to another investigational drug within 4 weeks prior to screening.

• Treatment with intravenous antibiotics within 3 weeks prior to screening.

• History of solid organ or hematological transplantation.

• Ongoing immunosuppressive therapy (other than corticosteroids).

• Positive hepatitis B surface antigen, hepatitis C antibody test or human immunodeficiency virus (HIV) test.

• Known portal hypertension.

• Pregnancy or breast-feeding.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• Ataluren
Ataluren will be administered per dose and schedule specified in the arm.

Locations

Country	Name	City	State
Belgium	Hôpital Universitaire des Enfants Reine Fabiola	Brussels
Belgium	University Hospital Brussels	Brussels
Belgium	University Hospital Leuven	Leuven
France	Hôpital Necker - Enfants Malades	Paris
France	Hôpital des Enfants	Toulouse
Israel	Hadassah University Hospital - Mount Scopus	Jerusalem
Italy	Università La Sapienza	Roma
Italy	Azienda Ospedaliera di Verona	Verona
Spain	Hospital Universitario La Paz	Madrid
Sweden	Karolinska University Hospital, Huddinge	Stockholm
United States	Denver Children's Hospital	Aurora	Colorado
United States	University of Alabama-Birmingham	Birmingham	Alabama
United States	Children's Hospital Boston	Boston	Massachusetts
United States	Children's Hospital Chicago	Chicago	Illinois
United States	Rainbow Babies & Children's Hospital	Cleveland	Ohio
United States	Miller Children's Hospital Long Beach	Long Beach	California
United States	Beth Israel Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
PTC Therapeutics

Countries where clinical trial is conducted

United States,  Belgium,  France,  Israel,  Italy,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at the End of Treatment (Week 192), as Assessed by Spirometry	FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position. Percent of predicted FVC = (observed value)/(predicted value) * 100%. Change from baseline in percent predicted FVC at the end of treatment was reported.	Baseline, Week 192
Other	Change From Baseline in Percent Predicted Forced Expiratory Flow Between 25% and 75% of Expiration (FEF25-75) at the End of Treatment (Week 192), as Assessed by Spirometry	FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity.	Baseline, Week 192
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of an AE was classified as: mild (does not interfere with usual function), moderate (interferes to some extent with usual function), severe (interferes significantly with usual function), life threatening (results in potential threat to life), and fatal AEs. Drug-related AEs: AEs with a possible or probable relationship to study drug. Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention. TEAE: AE that occurred or worsened from first dose of study drug to 4 weeks after last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.	Baseline (Day 1) up to end of study (Week 196)
Primary	Number of Participants With Clinically Significant Laboratory Abnormalities	Laboratory parameters tests included hematology, biochemistry assay (hepatic, renal, and serum electrolyte values), adrenal assays, and urinalysis. Clinical significance was defined as per investigator's judgement.	Baseline (Day 1) up to end of study (Week 196)
Secondary	Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at the End of Treatment (Week 192), as Assessed by Spirometry	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Percent of predicted FEV1 = (observed value)/(predicted value) * 100%. Change from baseline in percent predicted FEV1 at the end of treatment was reported.	Baseline, Week 192
Secondary	Percentage of Participants With Pulmonary Exacerbation, As Assessed by Modified Fuchs Criteria	The modified Fuchs' criteria defined exacerbation as the presence of at least 4 of the following 12 Fuchs' signs and symptoms without the requirement for treatment with antibiotics: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; fatigue; temperature greater than (>) 38 degrees celsius (°C); anorexia; sinus pain; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent or more from a previously recorded value; or radiographic changes indicative of pulmonary function.	Baseline up to Week 192
Secondary	Percentage of Participants With Pulmonary Exacerbation, As Assessed by Expanded Fuchs' Criteria	The expanded Fuchs' criteria defined exacerbation as the presence of at least 4 of the following 12 Fuchs' signs and symptoms requiring any form of antibiotic treatment (inhaled, oral, or intravenous): change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; fatigue; temperature >38°C; anorexia; sinus pain; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent or more from a previously recorded value; or radiographic changes indicative of pulmonary function.	Baseline up to Week 192
Secondary	Percentage of Participants With Pulmonary Exacerbation, As Assessed by Classic Fuchs' Criteria	The Classic Fuchs' criteria defined exacerbation as the presence of at least 4 of the following 12 Fuchs' signs and symptoms requiring treatment with parenteral antibiotics: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; fatigue; temperature >38°C; anorexia; sinus pain; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent or more from a previously recorded value; or radiographic changes indicative of pulmonary function.	Baseline up to Week 192
Secondary	Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters at Final Visit (Week 196)	ECG parameters included RR duration, PR duration, QRS duration, QT duration, QTCB (Bazett's correction formula) duration, QTCF (Fridericia's correction formula) duration.	Baseline, Week 196
Secondary	Change From Baseline in Heart Rate at Final Visit (Week 196), as Assessed by 12-Lead ECG	Heart rate was measured using 12-lead ECG.	Baseline, Week 196
Secondary	Change From Baseline in Vital Signs at Final Visit (Week 196)	Vital Signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP).	Baseline, Week 196

External Links

•   PTC Therapeutics, Inc. website